Good Products Launches ValMan to Facilitate Validation Project Management
Good Products, a leading provider of Enterprise Content Management (ECM) solutions for the pharmaceutical and biopharmaceutical industries, announces the availability of its new Validation Project Management tool ValMan.
Good Products Launches ValMan™to Facilitate Validation Project Management
(12 August, 2008) Good Products, a leading provider of Enterprise Content Management (ECM) solutions for the pharmaceutical and biopharmaceutical industries, announces the availability of its new Validation Project Management tool ValMan™. This unique software helps life sciences organizations to store and manage validation protocols and test plans, enabling compliance with the strict regulations governing the industry. ValMan™ is available as part of the g-docs™ suite which is designed to streamline document management. A free of charge demo can be accessed via ValMan@goodproductsEU.com
Within the life sciences industry, multiple validation systems have traditionally been used to manage validation documents and projects, with individual templates being created for each project. Companies are now finding these processes extremely time-consuming and costly, and are looking for more streamlined and cohesive alternatives. Good Products has developed ValMan™ to provide a cost-effective, practical and complete validation project management system, and as the regulations and requirements change then protocols, templates and master plans are updated automatically.
ValMan™ enhances Good Products’ existing portfolio of eDMS solutions, which offer organizations regulatory-compliant, effective and easy-to-use methods of tracking documents and managing approvals. ValMan™ allows users to manage multiple validation projects in a clear and organized format, with the status of each of the products visible on a high level portfolio page.
The ValMan™ software tool allows documents and activities for specific projects to be stored in separate secure areas, while a set of predetermined workflow templates facilitates effective project management. Version control of all documents is carried out within ValMan™ and approved documents are published to a separate library for added user convenience. Product training is minimal as users are already familiar with the web browser environment of the g-docs™ platform and once ValMan™ is implemented, administrators control the ability to configure future libraries, templates and workflows.
ValMan™ customers can choose from a database of over 5,000 validation template documents covering facilities, cleaning, manufacturing equipment, laboratory equipment and computerized systems for biopharma, laboratory and clinical organizations to pre-populate their validation document libraries. ValMan™ also contains pre-configured project workflows, although companies’ existing templates, responsibility matrices, protocol review and approval workflows can also be entered quickly into the system. Within ValMan™, documents are stored on the g-docs™ MOSS 2007 platform and can be easily integrated with existing software systems, such as training management and learning management systems. Electronic documents and protocol deviation forms can be easily digitally signed using the CoSign® digital signature solution.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
